These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6414500)

  • 1. Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing.
    Rapeport WG; Mendelow AD; French G; MacPherson P; Teasdale E; Agnew E; Thompson GG; Brodie MJ
    Br J Clin Pharmacol; 1983 Oct; 16(4):365-9. PubMed ID: 6414500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Serum-Free and Cerebrospinal Fluid Valproic Acid Levels in Patients With Hypoalbuminemia After Craniotomy.
    Li Z; Gao W; Liu G; Chen W
    Ther Drug Monit; 2020 Aug; 42(4):610-616. PubMed ID: 32106182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of valproate and its active metabolites into cerebrospinal fluid of children with epilepsy.
    Löscher W; Nau H; Siemes H
    Epilepsia; 1988; 29(3):311-6. PubMed ID: 3131137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.
    Riva R; Albani F; Baruzzi A; Galvani I; Perucca E
    Ther Drug Monit; 1982; 4(4):341-52. PubMed ID: 6818733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
    Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
    Morikawa N; Mori T; Abe T; Kawashima H; Takeyama M; Hori S
    Biol Pharm Bull; 2000 Jun; 23(6):784-7. PubMed ID: 10864038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
    Cramer JA; Mattson RH
    Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filtration for free drug level monitoring: carbamazepine and valproic acid.
    Levy RH; Friel PN; Johno I; Linthicum LM; Colin L; Koch K; Raisys VA; Wilensky AJ; Temkin NR
    Ther Drug Monit; 1984; 6(1):67-76. PubMed ID: 6424279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear binding of valproic acid (VPA) and E-delta 2-valproic acid to rat plasma proteins.
    Semmes RL; Shen DD
    Pharm Res; 1990 May; 7(5):461-7. PubMed ID: 2114617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo plasma protein binding interaction between valproic acid and naproxen.
    Grimaldi R; Lecchini S; Crema F; Perucca E
    Eur J Drug Metab Pharmacokinet; 1984; 9(4):359-63. PubMed ID: 6442704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study.
    Lindberger M; Tomson T; Wallstedt L; Ståhle L
    Epilepsia; 2001 Feb; 42(2):256-61. PubMed ID: 11240599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid.
    Monaco F; Piredda S; Mutani R; Mastropaolo C; Tondi M
    Epilepsia; 1982 Feb; 23(1):23-6. PubMed ID: 6799283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of total and free valproic acid during monotherapy in infants.
    Herngren L; Lundberg B; Nergårdh A
    J Neurol; 1991 Sep; 238(6):315-9. PubMed ID: 1940980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diurnal oscillations in plasma protein binding of valproic acid.
    Patel IH; Venkataramanan R; Levy RH; Viswanathan CT; Ojemann LM
    Epilepsia; 1982 Jun; 23(3):283-90. PubMed ID: 6806086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EMIT FreeLevel ultrafiltration technique compared with equilibrium dialysis and ultracentrifugation to determine protein binding of phenytoin.
    Oellerich M; Müller-Vahl H
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():61-70. PubMed ID: 6705428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
    Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
    Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of valproic acid in volunteers after a single dose study.
    Bialer M; Hussein Z; Raz I; Abramsky O; Herishanu Y; Pachys F
    Biopharm Drug Dispos; 1985; 6(1):33-42. PubMed ID: 3921078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the Variables Influencing Valproic Acid Concentration in the Serum and Cerebrospinal Fluid of Chinese Patients After Craniotomy.
    Li Z; Gao W; Liu G; Chen W
    Ther Drug Monit; 2017 Aug; 39(4):450-456. PubMed ID: 28604475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.
    Gugler R; Mueller G
    Br J Clin Pharmacol; 1978 May; 5(5):441-6. PubMed ID: 350249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Simple and Rapid Method to Measure Free Fraction of Valproic Acid in Plasma Using Ultrafiltration and Ultra High Performance Liquid Chromatography-Mass Spectroscopy: Application to Therapeutic Drug Monitoring.
    Xu S; Chen Y; Zhao M; Zhao L
    Ther Drug Monit; 2017 Oct; 39(5):575-579. PubMed ID: 28700449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.